Abstract
The Revivent TC™ TransCatheter Ventricular Enhancement System
(BioVentrix Inc, San Ramon, CA, USA) is intended for use in heart
failure with cardiac dysfunction a previous myocardial infarction. The
resultant increased left ventricular systolic volume and discrete,
contiguous, non-contractile (akinetic and/or dyskinetic) scar located in
the antero-septal, apical (may extend laterally) region of the left
ventricle (LV) lends itself to Revivent. The procedure, called Less
Invasive Ventricular Enhancement (LIVE), consists of the implantation of
a series of micro-anchors pairs in order to exclude the scarred
myocardium, in order to reduce and reshape the LV. We present the
procedure step-by-step, as team coordination between the cardiac surgeon
and the interventional cardiologist is essential to ensure good
procedural outcomes. This is a novel and new technique to address Heart
Failure secondary to Myocardial Infarction.